Tag: Oncology
PharmaSignal — Oncology therapeutic area
Lilly boosts ADC portfolio with CrossBridge Bio deal
BioPharma Dive
Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies.
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Pharmaceutical Business Review
The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy.
Revolution rockets on strong pancreatic cancer data
Pharmaphorum
Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Pharmaceutical Technology
MSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC.
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma
BioPharma Dive
Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.
Allogene stock sails after CAR T clears residual lymphoma in early data cut
BioSpace
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
Revolution rises 40% as pancreatic cancer drug doubles survival
BioSpace
In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy
BioSpace
Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC i
IDEAYA/Servier PKC drug aces uveal melanoma trial
Pharmaphorum
Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.
FDA issues complete response letter to Replimune’s RP1 for melanoma
Pharmaceutical Business Review
The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
Data backs GSK’s ovarian cancer blockbuster hopes
Pharmaphorum
GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.
FDA issues complete response letter to Replimune’s RP1 for melanoma
Pharmaceutical Technology
The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy.
FDA hands another rejection to Replimune’s melanoma therapy
Pharmaphorum
Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors
BioPharma Dive
The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.
Roche places a $1bn bet on C4T degrader-antibody conjugates
Pharmaphorum
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
Pharmaceutical Technology
Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Pharmaceutical Technology
Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.
Kainova expands DT 7012 trial into Europe
PharmaTimes
First patient dosed as DOMISOL study grows beyond Australia
Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors
BioSpace
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.